ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 563

The Impact of Sex and Disease Classification on Patient-reported Outcome Measures in Axial Spondyloarthritis: A Descriptive Prospective Cross-sectional Study

Rikke Andreasen1, Lars Erik Kristensen 2, Kenneth Egstrup 1, Xenofon Baraliakos 3, Vibeke Strand 4, Hans Christian Horn 5, Inger Marie Hansen 1, Robin Christensen 6 and Torkell Ellingsen 7, 1Odense University Hospital, Svendborg, Svendborg, Denmark, 2Musculoskeletal Statistics Unit, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany, Herne, Germany, 4Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 5Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark, Odense, Denmark, 6Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital & Department of Rheumatology, Institute of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark, 7Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: ,

Session Information

Date: Sunday, November 10, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To explore the impact of sex and disease classification on outcomes in axial spondyloarthritis (axSpA) patients, including both ankylosing spondylitis (AS) and non-radiographic (nr-) axSpA, in males and females respectively.

Methods: AxSpA patients were consecutively recruited from 2 rheumatology outpatient university clinics. We explored how sex and axSpA disease classification affected patient-reported outcome measures (PROMs). Statistical tests were applied for group comparisons and interactions. We analyzed the relationship between tender point count (TPC) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). The prevalence of extra-articular manifestations (EAMs) and the Charlson comorbidity index (CCI) were determined.

Results: According to the protocol a total of 100 outpatients with axSpA were enrolled (AS males 30; AS females 10; nr-axSpA males 25; nr-axSpA females 35). The BASDAI scores appeared higher among nr-axSpA females (median [Q1; Q3] 47 [21; 60]) compared with the combined median for the three other subgroups 25 [12; 25]. Being classified as nr-axSpA was associated with a lower SF-36 MCS (median SF-36 MCS for the four subgroups: nr-axSpa females: 46.7, nr-axSpA males: 52.3 vs. AS males: 56.9 and AS females: 50.4). Females had a higher tender point count (TPC) compared with females (P< 0.001). TPC and BASDAI were correlated for female nr-axSpA patients (r= 0.44, P=0.008) and male nr-axSpA patients (r= 0.56, P=0.003). EAMs were frequent (up to 50 %) and no difference in the CCI between the subgroups was observed (P=0.14).

Conclusion: This is to our knowledge the first study to evaluate the impact of sex and axSpA classification on PROMs in axSpA patients. AS patients appeared less affected on most PROMs compared with nr-axSpA patients.

Figure 1. Mean SF-36 scores for Danish axSpA patients stratified on sex and axSpA classification. -A- nr-axSpA females -B- nr-axSpA males -C- AS females -D- AS males. Mean SF-36 scores for Danish norms are also shown. PF, physical function; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; MH, mental health.


Table 1

Table 1.Clinical characteristics and patient-reported outcome measures

Disclosure: R. Andreasen, None; L. Kristensen, Pfizer, 8, AbbVie, 8, Amgen, 8, UCB, 8, Biogen, 8, MSD, 8, Sanofi, 8, Novartis, 8, Eli Lilly and company, 8, Janssen pharmaceutical, 8; K. Egstrup, None; X. Baraliakos, AbbVie, 2, 8, Pfizer, 2, 8, Novartis, 2, 8, MCD, 2, 8, UCB, 2, 8, Roche, 2, 8, Celgene, 2, 8, Janssen, 2, 8; V. Strand, Abbvie, 5, AbbVie, 5, Amgen, 5, Amgen, Abbvie, Bayer, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, UCB, 5, AstraZeneca, 5, AURA, 8, Bayer, 5, BMS, 5, Boehringer Ingelheim, 5, Celgene, 5, Celltrion, 5, Cleveland Clinic, 8, CORRONA, 5, Crescendo, 5, Crescendo Bioscience, 5, Eli Lilly, 5, EMD Serono, 5, Genentech, 5, GlaxoSmithKline, 5, GSK, 5, Horizon, 5, Inmedix, 5, Janssen, 5, Kezar, 5, Lilly, 5, Merck, 5, NACCME, 8, Novartis, 5, Pfizer, 5, Purdue, 8, RA Forum, 8, RAN, 8, Regeneron, 5, Roche, 5, Samsung, 5, Sandoz, 5, Sanofi, 5, Servier, 5, Setpoint, 5, SLRA, 8, UCB, 5, Up to Date, 7, Washington University, 8, WIR, 8, WRA, 8; H. Horn, None; I. Hansen, None; R. Christensen, AbbVie, 2, Amgen, 2, Axellus A/S, 2, Biogen, 2, BMS, 2, cambridge weight plan, 2, Celgene, 2, Eli Lilly, 2, Hospira, 2, MSD, 2, Norpharma, 2, Novartis, 2, Oak Foundation (OCAY-13-309), 2, Orkla Health, 2, Pfizer, 2, Research Unit for Musculoskeletal Function and Physiotherapy, Institute of Sports science and Clinical biomechanics, University of Southern Denmark, 9, Roche, 2, Sobi, 2, Takeda, 2; T. Ellingsen, None.

To cite this abstract in AMA style:

Andreasen R, Kristensen L, Egstrup K, Baraliakos X, Strand V, Horn H, Hansen I, Christensen R, Ellingsen T. The Impact of Sex and Disease Classification on Patient-reported Outcome Measures in Axial Spondyloarthritis: A Descriptive Prospective Cross-sectional Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-impact-of-sex-and-disease-classification-on-patient-reported-outcome-measures-in-axial-spondyloarthritis-a-descriptive-prospective-cross-sectional-study/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-sex-and-disease-classification-on-patient-reported-outcome-measures-in-axial-spondyloarthritis-a-descriptive-prospective-cross-sectional-study/